{
    "code": 0,
    "data": [
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results_31.12.2025",
            "news_body": "Unaudited standalone and consolidated financial results for the quarter ended 31.12.2025.",
            "news_id": "c81c362b-fdad-43ca-b034-e924b1228680",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=02b038d5-d692-43e3-926a-a3c2ae50863a.pdf",
            "news_date": "2026-02-11 19:03:12",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Financial Results_31.12.2025",
            "news_body": "Unaudited standalone and consolidated financial results for the quarter ended 31.12.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=02b038d5-d692-43e3-926a-a3c2ae50863a.pdf",
            "news_date": "2026-02-11 19:03:12"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting_ Standalone And Consolidated Financial Results For The  Quarter Ended 31.12.2025.",
            "news_body": "Unaudited standalone and consolidated financial results for the quarter ended 31.12.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=09acae17-8acf-4cbc-ba43-7b14a1b04f2e.pdf",
            "news_date": "2026-02-11 18:32:12"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Outcome",
            "descriptor": "Postal Ballot",
            "caption": " Shareholder Meeting / Postal Ballot-Scrutinizer\"s Report",
            "news_body": "Dr.Mukesh Beekamchand ( DIN # 11295580 ) is appointed as Non executive Independent Director of the Company through an ordinary resolution passed by the members of the Company through postal ballot.\r\nScrutinizers reports dated 09.02.2026 is attached.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f0c26c88-4f5d-4601-a345-36bd67f5ab01.pdf",
            "news_date": "2026-02-09 18:34:54"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended 31.12.2025.",
            "news_body": "Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve Unaudited standalone and consolidated financial results of the Company for the quarter ended 31.12.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b00785f4-bc31-4ecc-b7a1-b9627296da90.pdf",
            "news_date": "2026-02-03 15:50:48"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "We are submitting newspaper advertisements of the postal ballot notice issued by the Company on 08.01.2026 and published on 09.01.2026.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17eb7610-4dad-4d9f-8212-c7f9688b884a.pdf",
            "news_date": "2026-01-12 16:50:52"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Confirmation as per Regulation 74(5) of SEBI(DP) Regulations for the quarter ended 31.12.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=37205bf0-c948-4c3e-b588-7b022feffe4f.pdf",
            "news_date": "2026-01-09 12:18:35"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Intimation",
            "descriptor": "Postal Ballot",
            "caption": "Shareholder Meeting / Postal Ballot-Notice of Postal Ballot",
            "news_body": "Postal Ballot notice for appointment of Dr.Mukesh Beekamchand ( DIN # 11295580) as independent Director of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=69157e3a-b8aa-4aa2-82ce-325391f6ae64.pdf",
            "news_date": "2026-01-08 15:59:56"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Trading Window Closure from 1st January 2026 to 16th February 2026- for announcing unaudited financial results for the quarter ended 31.12.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a8d56e57-4092-4a9f-a36e-d49242c1087d.pdf",
            "news_date": "2025-12-23 12:49:09"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "We are submitting to the exchanges news paper advertisements of the unaudited standalone and consolidated financial results of the company for the quarter ended 30.09.2029 announced by the company on 12.11.2025 and published in financial express and Sanjayvani on 14.11.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=07f5ba90-44ac-43ae-beb1-2c6aea42b646.pdf",
            "news_date": "2025-11-17 16:17:30"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30.09.2025",
            "news_body": "Unaudited standalone and Consolidated financial results for the quarter ended 30.09.2025.",
            "news_id": "03fce482-e86e-46fd-8e98-f439c72b9a45",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=42dde0cc-3aff-405f-9f73-ecd86fafc6a5.pdf",
            "news_date": "2025-11-12 18:56:34",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30.09.2025",
            "news_body": "Unaudited standalone and Consolidated financial results for the quarter ended 30.09.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=42dde0cc-3aff-405f-9f73-ecd86fafc6a5.pdf",
            "news_date": "2025-11-12 18:56:34"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting_12.11.2025",
            "news_body": "Board of Directors of the Company has inter alia 1. Approved the unaudited standalone and consolidate financial results for the quarter ended 30.09.2025. 2. Appointed Dr.B.Mukesh ( DIN # 11295580)as additional Director of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=74daebaf-01d6-4548-862c-ef652f22b8cd.pdf",
            "news_date": "2025-11-12 18:49:21"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Update On The Outcome Of The Board Meeting Held On 11.08.2025",
            "news_body": "Clarification on the outcome of the board meeting held on 11.08.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a95af25e-d4cd-411d-83c1-ba421115cd98.pdf",
            "news_date": "2025-11-07 15:00:38"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Unaudited Financial Results",
            "news_body": "Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve standalone and consolidated financial results of the Company for the quarter and half year ended 30.09.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0836e722-95af-43b2-9f76-5c3b3169039d.pdf",
            "news_date": "2025-11-04 16:44:53"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Confirmation as per Regulation 74(5) of SEBI(DP) Regulations for the quarter ended 30.09.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85091692-195f-477e-badf-380c844644e4.pdf",
            "news_date": "2025-10-06 12:11:17"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Directorate",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate",
            "news_body": "Completion of term of Mr.H.S Venkatesh ( DIN # 01776040) as Independent Director of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=509b31db-635c-4640-bbb2-9a242cfda3dd.pdf",
            "news_date": "2025-09-30 15:12:35"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Trading Window on dealing with the securities of the Company will be closed from 1st October 2025 until 48 hours of announcement of Unaudited financial results of the Company for the qtr ended 30.09.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=71b3eee9-a589-4651-b0ac-dc866ee195bc.pdf",
            "news_date": "2025-09-26 16:18:05"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Outcome of AGM",
            "news_body": "Outcome of the 38th Annual General Meeting of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7d109d09-226a-470b-b89f-1bb058492a36.pdf",
            "news_date": "2025-09-25 15:41:09"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newpaper Publication for Notice for the 38th Annual General Meeting of the Company together with e-voting and Book closure .",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=983f4936-3e76-4407-a329-778c81a3f798.pdf",
            "news_date": "2025-09-03 16:13:20"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Reg. 34 (1) Annual Report",
            "caption": "Reg. 34 (1) Annual Report.",
            "news_body": "We are submitting the Copy of the unabridged Annual Report for the financial year ended 31.03.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b01f19bc-25b0-4203-89d9-9935cdf36795.pdf",
            "news_date": "2025-09-02 15:26:48"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newpaper Publication of the Unaudited financial results for the quarter ended 30.06.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=83a84a08-b866-421c-a41b-ad314b92d27b.pdf",
            "news_date": "2025-08-13 17:00:49"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Intimation",
            "descriptor": "Record Date",
            "caption": "Corporate Action-Fixes Record Date For Dividend.",
            "news_body": "The Board of Directors at their meeting held on 11.08.2025 has fixed 18th September 2025 as record date for the payment of dividend for the financial year ended 31.03.2025 which is subject to the approval of the shareholders at the 38th AGM of the Company convened to be held on 25.09.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee68edd5-36f1-4dc0-8c6c-4de5d1de4609.pdf",
            "news_date": "2025-08-12 17:38:02"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial For The Quarter Ended 30.06.2025.",
            "news_body": "Unaudited financial results ( Standalone and consolidated )  for the quarter ended 30.06.2025.",
            "news_id": "e62b311d-ea2f-4a8f-b4a2-09dcee381e3e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5da811ea-f250-4bf0-af0d-ec193eca38b5.pdf",
            "news_date": "2025-08-11 18:09:49",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited Financial For The Quarter Ended 30.06.2025.",
            "news_body": "Unaudited financial results ( Standalone and consolidated )  for the quarter ended 30.06.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5da811ea-f250-4bf0-af0d-ec193eca38b5.pdf",
            "news_date": "2025-08-11 18:09:49"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "Board of Directors of the Company has met today and inter alia transacted the following business\r\n1. Approved the unaudited financial results ( standalone and consolidated ) for the quarter ended 30.06.2025.\r\n2. Convened 38th Annual General meeting of the company on 25th September 2025 at 11.30 am through AV means.\r\n3. Decided to close the register of members from 19.09.2025 to 25.09.2025 ( both days inclusive )\r\n4. Approved the ESOP -2025 plan subject to the approval of shareholders.\r\n5. e-Voting dates from 22.09.2025 to 24.09.2025 for the ensuing Annual General Meeting.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d0e8db01-4732-4a00-9928-0185bebc3c10.pdf",
            "news_date": "2025-08-11 18:04:21"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Inter Alia Take On Record And Approve The Unaudited Financial Results For The Quarter Ended 30.06.2025.",
            "news_body": "Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2025 inter alia to consider and approve 1. Unaudited financial results for the quarter ended 30.06.2025.\r\n2.Convene 38th Annual General Meeting of the Company. \r\n3.To Fix Book Closure dates. \r\n4. Employee Stock Option Plan -2025\r\n5.Merger of Lifezen healthcare Pvt Ltd (Subsidiary) with Bal Pharma Ltd (Holding Company)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a6092c6d-0aec-4df2-a336-cbe861d79fd7.pdf",
            "news_date": "2025-07-29 16:47:31"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "We are submitting to the exchanges newspaper advertisements of the notice issued to the shareholders regarding transfer of their shares to IEPF account  whose dividend is outstanding to be claimed from the year 2017.18.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=173520b4-c703-46b2-a037-31fbbbd4fa6d.pdf",
            "news_date": "2025-07-10 17:22:34"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Certificate under Regulation 74(5) of SEBI(DP) Regulations for the quarter ended 30.06.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=52dde581-d378-4a6e-95fe-991447c05b25.pdf",
            "news_date": "2025-07-03 13:04:32"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newpaper publication of the Postal Ballot notice dated 30.06.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9c1b94e4-a934-4fef-8edc-46600270630c.pdf",
            "news_date": "2025-07-02 15:00:08"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Intimation",
            "descriptor": "Postal Ballot",
            "caption": "Shareholder Meeting / Postal Ballot-Notice of Postal Ballot",
            "news_body": "Postal Ballot Notice",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=60803bbc-fc26-4118-9c3a-b8368c3b9fa1.pdf",
            "news_date": "2025-06-30 12:22:16"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Trading window for dealing with the securities of the Company on designated persons and their relatives will be closed from 1st July 2025 up to 48 hours of announcing the unaudited financial results of the company for the quarter ended 30.06.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=29213d4a-4888-4d56-acb2-2244a448ac5a.pdf",
            "news_date": "2025-06-20 11:22:19"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation To The Physical Shareholders For Updating KYC.",
            "news_body": "We are submitting to the exchange a copy of the intimation sent to our physical shareholders for updating their KYC.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=49263d9e-4caf-4c75-86aa-b923a0b8614f.pdf",
            "news_date": "2025-06-16 16:15:52"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Compliance",
            "descriptor": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure ",
            "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
            "news_body": "  <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Bal Pharma Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85110KA1987PLC008368</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>43.64</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>BBB-</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>ACUITE RATINGS & RESEARCH LIMITED</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table>  <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: MrAbdul Basith <br/>  Designation: Company Secretary and Compliance Officer <br/> EmailId: secretarial@balpharma.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: MrBharath Bhushan <br/> Designation: CFO <br/> EmailId: accounts@balpharma.com</div> </div> <div> <br/> Date: 16/06/2025<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac7049c9-1677-4092-a96e-78e6b86dfde4.pdf",
            "news_date": "2025-06-16 13:18:34"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Published audited financial results for the quarter and financial year ended 31.03.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d76d524d-60bb-4479-85e3-e0c34c725c90.pdf",
            "news_date": "2025-06-02 11:41:22"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The  Board Meeting-Audited Financial Results And Recommendation Of Dividend",
            "news_body": "Board of Directors at their meeting held on 29.05.2025 has inter alia  approved \r\n\r\n1. Audited financial results for the financial year ended 31.03.2025\r\n2. Recommended a dividend of Rs.1.20 per equity share of Rs.10 each i.e 12%\r\n3. Appointment of Secretarial Auditor Cost auditor and Internal Auditor. \r\n",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4775c974-3a1d-415e-acc9-07d88e20591b.pdf",
            "news_date": "2025-05-29 17:52:23"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Compliance",
            "descriptor": "Reg.24(A)-Annual Secretarial Compliance",
            "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
            "news_body": "Annual Secretarial Compliance Report for the financial year ended 31.03.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6a1938f7-1d14-47ad-83a7-74562d7a18cf.pdf",
            "news_date": "2025-05-27 16:58:23"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Resignation of Director",
            "caption": "Announcement under Regulation 30 (LODR)-Resignation of Director",
            "news_body": "Mr.Kotain Chittanand Damodar (DIN # 09613054) has tendered his resignation as Whole Time Director of the Company w.e.f 16.05.2025 citing personal reasons.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=453e2149-ebe4-435b-b271-e4429bb941a5.pdf",
            "news_date": "2025-05-16 14:49:50"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Approval Of Audited Financial Results Of The Company And Recommendation Of Dividend Is Any For The Financial Year Ended 31.03.2025.",
            "news_body": "Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 inter alia to consider and approve 1. Audited financial results for the quarter and financial year ended 31.03.2025.\r\n2. Audited standalone and consolidated accounts of the Company together with reports of Directors and auditors there on.\r\n3. Recommendation of Dividend if any for the financial year 2024.25.\r\n4.Appointment of Internal Auditors and Cost Auditors for the financial year 2025.26\r\n5. Appointment of Secretarial Auditors for five consecutive years  subject to the approval of shareholders.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9c6bbcd1-2064-4150-b0cd-a08f9becf34b.pdf",
            "news_date": "2025-05-15 17:32:03"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "The Board of Directors of the Company through a resolution passed by circulation has appointed Mr.Ravindra Kumar Kothari ( DIN # 03418320) as Additional Director ( Non-Executive and Non-Independent) of the Company to hold office until the conclusion of the ensuing Annual General Meeting of the Company or within three months from the date of appointment whichever is earlier.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cf777943-c408-4dcf-af26-637106c16414.pdf",
            "news_date": "2025-05-05 16:09:01"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Compliance",
            "descriptor": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure ",
            "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
            "news_body": "  <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Bal Pharma Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85110KA1987PLC008368</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>43.14</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>BBB-</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>ACUITE RATINGS & RESEARCH LIMITED</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table>  <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: ABDUL BASITH <br/>  Designation: Company Secretary and Compliance Office <br/> EmailId: secretarial@balpharma.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: BHARATH BHUSHAN <br/> Designation: CFO <br/> EmailId: accounts@balpharma.com</div> </div> <div> <br/> Date: 24/04/2025<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=32ab95f3-eff4-4976-b54f-bd2490938c28.pdf",
            "news_date": "2025-04-24 16:42:07"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Update On Application Filed For Reclassification Of Promoters",
            "news_body": "As per the provisions of Regulation 31A of SEBI(LODR) Regulations we are herewith withdrawing our application for reclassification of promoters.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3eb8e398-709c-4173-9760-9ff1e83cd31c.pdf",
            "news_date": "2025-04-18 11:07:27"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "We are submitting  the certificate in compliance with Regulation 74(5) of SEBI(DP) Regulations for the quarter ended 31.03.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8139f025-0e90-4392-8b01-a3c35ba2a898.pdf",
            "news_date": "2025-04-04 11:52:22"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Scheme of Arrangement",
            "caption": "Announcement under Regulation 30 (LODR)-Scheme of Arrangement",
            "news_body": "Honble NCLT  Bangalore bench has approved the scheme of arrangement between Golden Drugs Pvt Ltd ( Transferer Company)  a wholly owned subsidiary of the Company with Bal Pharma Ltd ( Transferee Company ) vide its order dated 26.03.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=efd798f2-55f3-4a08-8c8b-2efe319fbe76.pdf",
            "news_date": "2025-03-28 15:12:33"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Trading window for dealing with the securities of the Company on designated persons and their immediate relatives will be closed from 1st April 2025 and upto 48 hours of announcing the audited financial results of the Company for the financial year ended 31.03.2025.\r\nThe date of the Board meeting for announcing the audited financial results will be intimated to the exchanges shortly.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2e446509-a391-4584-97d5-08e999fe6f0e.pdf",
            "news_date": "2025-03-25 16:13:19"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Withdrawal Of Promoter Reclassification Request.",
            "news_body": "Withdrawal of reclassification application made with the exchanges as per the provisions of Regulation 31A of SEBI(LODR) Regulations2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f460275b-4785-4a3c-9efb-9f868fc3bb85.pdf",
            "news_date": "2025-03-20 11:45:14"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Meeting Updates",
            "caption": "Announcement under Regulation 30 (LODR)-Meeting Updates",
            "news_body": "Additional details for Corporate Announcement filed under Regulation 30 of SEBI(LODR)Regulations2015 dated 13.02.2025.\r\n",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ffc42d41-70e5-4431-a30c-ec210f2b9710.pdf",
            "news_date": "2025-02-18 12:18:10"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "We are submitting to the exchange newspaper advertisements of abridged unaudited standalone and consolidated financial results for the quarter ended 31.12.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=05182acb-aee1-4b5f-9638-64b5a14f652a.pdf",
            "news_date": "2025-02-17 15:46:05"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Integrated Filing (Financial)",
            "caption": "Integrated Filing (Financial)",
            "news_body": "We are submitting to the exchange  integrated filing ( Finance) for the quarter ended 31.12.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=437a7473-579d-4f81-9203-6ea6424ccf8d.pdf",
            "news_date": "2025-02-14 16:40:27"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Standalone And Consolidated Financial Results For The Quarter Ended 31.12.2024.",
            "news_body": "The Board of Directors at their meeting held on 13.02.2025 has taken on record and approved Un audited financial results of the Company for the quarter ended 31.12.2024.\r\n\r\nCopy of the financial results together with limited review report issued by statutory auditors is enclosed.",
            "news_id": "882a9bb3-9f77-410b-8d3d-b41d62841645",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=60694750-63e0-4871-8d03-a6ff0fe2011a.pdf",
            "news_date": "2025-02-13 18:14:22",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Standalone And Consolidated Financial Results For The Quarter Ended 31.12.2024.",
            "news_body": "The Board of Directors at their meeting held on 13.02.2025 has taken on record and approved Un audited financial results of the Company for the quarter ended 31.12.2024.\r\n\r\nCopy of the financial results together with limited review report issued by statutory auditors is enclosed.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=60694750-63e0-4871-8d03-a6ff0fe2011a.pdf",
            "news_date": "2025-02-13 18:14:22"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30.09.2024.",
            "news_body": "The Board of Directors at their meeting held on 13.02.2025 has inter alia taken on record and approved the stand alone and consolidated financial results of the Company.\r\n\r\nCopy of financial results  Limited review report issued by statutory auditors together with declaration of unmodified opinion is enclosed . \r\n\r\nPlease take the same on record.",
            "news_id": "6ed05334-7b0a-45a9-af79-6e2ec7b53d36",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6b9c1503-551d-46b8-aea6-dbc9b11688d0.pdf",
            "news_date": "2025-02-13 17:44:34",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30.09.2024.",
            "news_body": "The Board of Directors at their meeting held on 13.02.2025 has inter alia taken on record and approved the stand alone and consolidated financial results of the Company.\r\n\r\nCopy of financial results  Limited review report issued by statutory auditors together with declaration of unmodified opinion is enclosed . \r\n\r\nPlease take the same on record.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6b9c1503-551d-46b8-aea6-dbc9b11688d0.pdf",
            "news_date": "2025-02-13 17:44:34"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "Board of Directors at their meeting held on 13.02.2024 has inter alia \r\n\r\n1.Taken on record and approved Unaudited stand alone and consolidated financial results for the quarter and 9 months ended 31.12.2024.\r\n2. Differed to consider fund raising options due to unfavorable and volatile market conditions.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7a045eb3-fb8b-4db3-b854-8149299ad6e7.pdf",
            "news_date": "2025-02-13 17:37:35"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Board Meeting Intimation",
            "news_body": "BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve Unaudited standalone and consolidated financial results for the quarter ended 31.12.2024 and to consider fund raising options .",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ec6fa41-7d8b-457b-a683-8d85fde6aad8.pdf",
            "news_date": "2025-01-24 17:57:43"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Compliance certificate as per Regulation 74(5) of DP Regulations for the quarter ended 31.12.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=56b9ef91-e899-40ca-905b-f455f096d723.pdf",
            "news_date": "2025-01-06 12:21:25"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Change In The Name Of RTA",
            "news_body": "Name of our RTA is change from Link intime India Private Limited to MUFG Intime India Private Ltd w.e.f 31.12.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=df1c7511-870a-47fb-b98f-673cdde213cf.pdf",
            "news_date": "2025-01-02 18:31:49"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Meeting Updates",
            "caption": "Announcement under Regulation 30 (LODR)-Meeting Updates",
            "news_body": "As per Regulation 31 A (8)(b) of LODR Regulations, we are circulation the extract of the minutes of BOD held on 12.08.2024 pertaining to reclassification of promoters.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7d79406e-ca04-4ecc-8085-239d4eca3cb3.pdf",
            "news_date": "2024-12-03 15:29:41"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "We are submitting a copy of the newspaper publication regarding notice for the transfer of equity shares to IEPF a/c.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2f198916-956f-4de1-b40b-d7706608de9b.pdf",
            "news_date": "2024-11-28 12:41:29"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "General",
            "caption": "Disclosure Regarding Reclassification Of Promoter Group",
            "news_body": "As per Regulation 31A(8) (c) of SEBI LODR Regulations, we are disclosing submission of our application for reclassification of promoter group of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=69c9bef9-14bd-4053-92c4-9cbb7fc20263.pdf",
            "news_date": "2024-11-22 16:11:08"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "We are submitting the  copies of the published financial results of the Company for the quarter ended 30.09.2024,  in Financial Express and Snajay Vani,  on 15.11.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=395339f3-4c78-4ac2-9e97-6a0182ddf6b0.pdf",
            "news_date": "2024-11-15 16:15:14"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Board Meeting",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Un-Audited Financial Results For The Quarter & Half Year Ended 30.09.2024.",
            "news_body": "Un-Audited standalone and consolidated financial results for the quarter and half year ended 30.09.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3955036a-c094-49cd-9fb2-7df36df18a6e.pdf",
            "news_date": "2024-11-14 17:50:27"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Financial Results For The Quarter Ended 30.09.2024.",
            "news_body": "Board of Directors at their meeting held on 14.11.2024 has inter alia taken on record and approved the Un-audited financial results of the Company for the quarter and half year ended 30.09.2024.",
            "news_id": "a8959049-992a-4706-ade1-1c0539890571",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7826be06-be73-4b4d-9eef-504e2e17522a.pdf",
            "news_date": "2024-11-14 17:28:05",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Result",
            "descriptor": "Financial Results",
            "caption": "Un-Audited Financial Results For The Quarter Ended 30.09.2024.",
            "news_body": "Board of Directors at their meeting held on 14.11.2024 has inter alia taken on record and approved the Un-audited financial results of the Company for the quarter and half year ended 30.09.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7826be06-be73-4b4d-9eef-504e2e17522a.pdf",
            "news_date": "2024-11-14 17:28:05"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Board Meeting",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter And Half Year Ended 30.09.2024",
            "news_body": "BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 ,inter alia, to consider and approve Un-audited standalone and consolidated financial results of the company for the quarter and half year ended 30.09.2024",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=afc0c3a8-dfff-45f2-b625-9029c002bedb.pdf",
            "news_date": "2024-11-05 11:16:41"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "",
            "descriptor": "Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
            "caption": "Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
            "news_body": "Intimation regarding loss of share certificates, as per Regulation 39(3) of SSEBI(LODR) Regulations.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3e24c4d5-dfdc-482a-830e-71d84168917f.pdf",
            "news_date": "2024-10-18 18:31:15"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "",
            "descriptor": "Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
            "caption": "Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
            "news_body": "Intimation regarding issue of Duplicate share certificates as per Regulation 39(3) of SEBI(LODR) Regulations,2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=60777ad7-11ba-450f-ac7e-4fb80952fa0c.pdf",
            "news_date": "2024-10-15 14:39:02"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018",
            "news_body": "Certificate under Regulation 74(5) of SEBI(DP) Regulations,2018 for the quarter ended 30.09.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=351f5c68-8620-4f8d-8b18-17660f42c834.pdf",
            "news_date": "2024-10-04 15:48:26"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "",
            "descriptor": "Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
            "caption": "Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
            "news_body": "Disclosure of details of loss of share certificates.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9342207d-3f91-48d5-b530-dada1adb473d.pdf",
            "news_date": "2024-10-01 15:01:57"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Insider Trading / SAST",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Intimation regarding closure of Trading Window .",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9cdbf91e-74dc-4fd7-a6ea-1cf56c156b55.pdf",
            "news_date": "2024-09-27 15:50:09"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "AGM/EGM",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Scrutinizer''s Report",
            "news_body": "We are submitting the Scrutinizers report on the e-voting done at the 37th Annual General Meeting of the Company held on 25.09.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6e633ca6-197e-4731-9c8a-ac7794a078d6.pdf",
            "news_date": "2024-09-26 17:50:06"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "AGM/EGM",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Outcome of AGM",
            "news_body": "We are submitting to the exchanges the out come of the 37th Annual General Meeting of the Company held on 25.09.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9129435c-7f6e-4e71-b8d1-f18c41cb31c4.pdf",
            "news_date": "2024-09-25 12:40:33"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "General",
            "caption": "Addendum To The Outcome Of The Board Meeting",
            "news_body": "Further to our intimation to the exchanges reg the Outcome of Board meeting dated 09.09.2024, we would like to clarify that the actual cost of the project that is being undertaken at Kadechur KIADB Industrial area, Yadgir Distriact, Karnataka is estimated to be around Rs.40 Crores and not Rs.30 Crores as stated in our above mentioned intimation inadvertently.Request you to please take this intimation on record.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=63d124b1-b5c7-4ca7-a3a8-480b363b3865.pdf",
            "news_date": "2024-09-11 18:27:10"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Board Meeting",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "Outcome of the Board Meeting- Announcement under Regulation 30 of SEBI(LODR) Regulations.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c83a6940-3e84-44f4-a418-5731bbb28a40.pdf",
            "news_date": "2024-09-09 17:41:41"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "AGM/EGM",
            "descriptor": "AGM",
            "caption": "Notice For The 37Th Annual General  Meeting.",
            "news_body": "We are submitting to the exchange , Notice for the 37th Annual General Meeting of the Company scheduled to be held on 25th September 2024 at 11.30 A.M through AV means.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=86cd439d-0b7f-4583-8794-7ecf9e91ec1b.pdf",
            "news_date": "2024-09-02 16:46:54"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Board Meeting",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for 1. Allotment Of Equity Shares To The Employees Of The Company Upon Conversion Of Stock Options Vested On Them.2. To Consider Expanding Its Manufacturing Presence To Meet Growing Demand For API''s.",
            "news_body": "BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/09/2024 ,inter alia, to consider and approve 1. Allotment of equity shares to the employees of the Company upon conversion of stock options vested on them.2. To consider expanding its manufacturing presence to meet growing demand for API''s.3.Any other matters incidental to the business operations and ensuing AGM of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cdec6d3c-e976-4921-9975-4492850f8ecf.pdf",
            "news_date": "2024-08-30 18:02:10"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "37th Annual General Meeting Notice & Book closure Intimation.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a8bc6591-01fb-42f7-9abd-c2aaf3c57c09.pdf",
            "news_date": "2024-08-30 14:52:39"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "",
            "descriptor": "Reg. 34 (1) Annual Report",
            "caption": "Reg. 34 (1) Annual Report.",
            "news_body": "We are submitting the unabridged Annual Report of the  Company for the financial year ended 31.03.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=70bcdb41-c60f-4a73-ad38-9ec852bae1bc.pdf",
            "news_date": "2024-08-30 10:55:52"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "",
            "descriptor": "Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
            "caption": "Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
            "news_body": "Intimation as per Regulation 39(3) of SEBI(LODR) Regulations,2015 regarding issue of duplicate share certificates.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3cd8c323-4e16-4cbf-86de-0f7afa75aad2.pdf",
            "news_date": "2024-08-19 12:52:47"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "We are submitting to the exchanges copies of published results, for the quarter ended 30.06.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=93d2a4c1-cd3d-4de4-902e-6441d093f4ff.pdf",
            "news_date": "2024-08-14 12:10:02"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Corp. Action",
            "descriptor": "Book Closure",
            "caption": "Dividend And 37Th Annual General Meeting Of The Company.",
            "news_body": "Register of Members and Share Transfer books of the company will remain closed from 19th September 2024 to 25th September 2024 ( both days inclusive ) to ascertain the entitlement of Dividend and for 37th Annual General Meeting of the Company .",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee36086d-f978-4932-8833-3c03a28dbd94.pdf",
            "news_date": "2024-08-12 18:26:27"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30.06.2024.",
            "news_body": "Taken on record and Approved the Unaudited financial results of the  Company for the quarter ended 30.06.2024.",
            "news_id": "7a0ce33e-8bdf-45be-b8dd-857cc3d73aac",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dc83ca16-90dd-4131-8584-b60159279e4b.pdf",
            "news_date": "2024-08-12 18:04:10",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Result",
            "descriptor": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30.06.2024.",
            "news_body": "Taken on record and Approved the Unaudited financial results of the  Company for the quarter ended 30.06.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dc83ca16-90dd-4131-8584-b60159279e4b.pdf",
            "news_date": "2024-08-12 18:04:10"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Board Meeting",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "Inter alia 1.Taken on record and approved the Unaudited financial results of the Company for the quarter ended 30.06.2024.2. Convened 37th Annual General Meeting of the Company on 25th September 2024.3. Decided to close the Register of Members and Share transfer books of the Company from 19.09.2024 to 25.09.2024(both days inclusive ) to ascertain the entitlement of Dividend and for 37th AGM.4.Approved the re-classification of promoter share holding subject to the approval of shareholders.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2d881278-dd9c-484c-88e2-f8096220fff1.pdf",
            "news_date": "2024-08-12 18:00:18"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Board Meeting",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Inter Alia Take On Record And Approve The Un-Audited Financial Results For The Quarter Ended 30.06.2024.",
            "news_body": "BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 ,inter alia, to consider and approve 1. Un-Audited financial Results for the quarter ended 30.06.2024.2.To review the requests of the promoters for reclassification.3. To convene 37th Annual General Meeting of the Company.4. To Decide on Book Closure dates.5. Other AGM related matters.6. Allotment of equity shares to the employees of the Company upon conversion of stock options.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=16839284-829a-4ae2-a9dd-af3219686982.pdf",
            "news_date": "2024-07-26 14:43:04"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "",
            "descriptor": "Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
            "caption": "Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
            "news_body": "Disclosure of details of loss of share certificates as per regulation 39(3) of SEBI (LODR) Regulations,2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8b07a768-d689-4608-aa4a-abb757c2a35e.pdf",
            "news_date": "2024-07-16 16:27:04"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018",
            "news_body": "We are submitting the confirmation of compliance with Regulation 74(5) SEBI(DP) Regulations, for the quarter ended 30.06.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8abbdcab-91db-42b2-90ad-fa36a7304d21.pdf",
            "news_date": "2024-07-04 12:53:12"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Change in Directorate",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate",
            "news_body": "We would like to inform the exchanges that Dr.C.V Srinivas ( DIN# 04495304) Independent Director of the Company has completed his tenure of five years as Independent Director of  the Company and he ceases to be on the Board of the Company w.e.f 28.06.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=494f205b-5e56-4a8e-a3ca-921d72981df0.pdf",
            "news_date": "2024-06-28 17:05:37"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Insider Trading / SAST",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Trading Window of the  Company  on designated persons and their immediate relatives will be closed from 1st July 2024 until 48 hours of declaration of the Un Audited financial results for the quarter ended 30.06.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7917a445-eda9-4b84-bf96-5af1bbb0e8e9.pdf",
            "news_date": "2024-06-25 11:37:23"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "",
            "descriptor": "",
            "caption": "Disclosure under Regulation 30A of LODR",
            "news_body": "Disclosure as per Regulation 31 A of SEBI (LODR) Regulations- Intimation reg receipt of applications from promoters for reclassification of their shareholding in the Company as Public holding.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c47d2984-da30-41cf-94be-a3110870a3f6.pdf",
            "news_date": "2024-06-03 15:40:30"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "In compliance with Regulation 47 of SEBI(LODR) Regulations, we are submitting the newspaper advertisements of the abridged Audited standalone and consolidated financial results of the company for the quarter and year ended 31.03.2024 announced by the Company on 28.05.2024 and published in Financial Express ( English) and Snajayvani ( Kannada ) on 29.05.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ddd13db0-0468-48cd-95ba-3a08ebcbaa68.pdf",
            "news_date": "2024-05-30 11:54:22"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Corp. Action",
            "descriptor": "Dividend",
            "caption": "Corporate Action-Board approves Dividend",
            "news_body": "Board of Directors of the Company at their meeting held on 28.05.2024 has recommended payment of Dividend of Re.1.20 paise per equity share of Rs.10 each i.e 12%,  which is subject to the approval of the shareholders  of the Company at the ensuing Annual General Meeting .",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=46178e3b-5a85-4138-91fc-c2a52804f685.pdf",
            "news_date": "2024-05-29 15:25:51"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results_31.03.2024",
            "news_body": "Audited stand alone & Consolidated financial results for the quarter and financial year  ended 31.03.2024 to gather with declaration of unmodified opinion and audit reports issued by statutory auditors.",
            "news_id": "ba669cb8-5926-4b12-97c8-8164341bf681",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=47ef817f-7f7a-4f05-b43e-9c591c375841.pdf",
            "news_date": "2024-05-28 18:04:19",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Result",
            "descriptor": "Financial Results",
            "caption": "Audited Financial Results_31.03.2024",
            "news_body": "Audited stand alone & Consolidated financial results for the quarter and financial year  ended 31.03.2024 to gather with declaration of unmodified opinion and audit reports issued by statutory auditors.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=47ef817f-7f7a-4f05-b43e-9c591c375841.pdf",
            "news_date": "2024-05-28 18:04:19"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Board Meeting",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "Board of Directors of the  Company has met today and inter alia transacted the following business,1.Approved the audited financial results ( Stand alone & Consolidated ) for the quarter and financial year ended 31.03.2024. Copies of the approved financial results along with Declaration of Unmodified opinion and Audit reports issued by the statutory auditors are enclosed for submitting to the exchanges. 2. Recommended a Dividend of Rs.1.20 per equity share of Rs.10 each i.e 12% which is subject to the approval of shareholders at the ensuing AGM.2. Reappointed Mr.M.R Krishna Murthy, Cost Accountant as Cost Auditor , M/s Murugesh & Co, Chartered Accountants  as Internal auditors and Mr.Parameshwar Bhat, PCS as Secretarial Auditors of the Company for the F.Y 2024-25.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d445f749-8a0f-4901-ad28-0492e7248f94.pdf",
            "news_date": "2024-05-28 17:56:47"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Reg.24(A)-Annual Secretarial Compliance",
            "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
            "news_body": "We are submitting the Annual Secretarial Compliance report duly certificated by the practicing Company Secretary for the financial year ended 31.03.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f78a1df-f4fe-4596-8557-e0d9357b8a39.pdf",
            "news_date": "2024-05-27 12:58:02"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "",
            "descriptor": "Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
            "caption": "Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
            "news_body": "Intimation reg loss of Share Certificate",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2153f8fd-100e-47de-b751-b866a9522270.pdf",
            "news_date": "2024-05-21 13:05:22"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Corp. Action",
            "descriptor": "Dividend",
            "caption": "Corporate Action-Board to consider Dividend",
            "news_body": "Please refer to our intimation regarding Board Meeting dated 30.04.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=43c9d4c6-e5a8-4b23-9a70-b94b7e5463a6.pdf",
            "news_date": "2024-05-03 17:36:21"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Board Meeting",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Notice For The Board Meeting",
            "news_body": "BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 ,inter alia, to consider and approve 1.Audited Standalone and Consolidated financial results for the quarter and financial year ended 31.03.2024.2.Audited standalone and consolidated accounts of the Company together with Directors and Auditors reports.3. Recommendation of Dividend, if any, for the financial year ended 31.03.2024.4.Appoinment of Internal Auditors, Cost Auditors and Secretarial Auditors for f.y ended 31.03.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee4747c2-85d3-4489-ac81-ae1441b53f93.pdf",
            "news_date": "2024-04-30 11:48:31"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Reg. 32 (1), (3) - Statement of Deviation & Variation",
            "caption": "Disclosure Of Statement Of Deviation/Veriation",
            "news_body": "Disclosure of Deviation / variation in utilization of issue proceeds from the objects stated in the explanatory statement to the notice of the general meeting for the quarter ended 31.03.2024 is not applicable for our Company i.e Bal Pharma Limited , as the preferential issue proceeds has been fully utilized.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a3c96ead-68f9-4674-a566-617fc5e60a5b.pdf",
            "news_date": "2024-04-18 16:45:22"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "",
            "descriptor": "Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
            "caption": "Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
            "news_body": "We are submitting to the exchange intimation received from our R&T agent i.e Link Intime India Private Ltd, Mumbai regarding loss of share certificate by one of our shareholder.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2cee362d-c67f-4130-bf35-4ea82b80d02f.pdf",
            "news_date": "2024-04-17 12:44:05"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Reg. 40 (10) - PCS Certificate for Transfer / Transmission / Transposition",
            "caption": "Compliance With Regulation 40(9) Of SEBI(LODR) Regulations.",
            "news_body": "Compliance certificate as per Regulation 40(9) of SEBI(LODR) Regulations , for the financial year ended 31.03.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef7905fb-dfa7-4abf-abea-4528dc1955e9.pdf",
            "news_date": "2024-04-15 15:29:36"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "General",
            "caption": "Disclosures As Per Regulation 31(4) Of SEBI(SAST) Regulations.",
            "news_body": "We are submitting to the exchange disclosures by our promoters as per Regulation 31(4) of SEBI(SAST) Regulations for the financial year ended 31.03.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a2d121bf-f5c1-4bf2-88dd-370979438e59.pdf",
            "news_date": "2024-04-05 15:32:13"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018",
            "news_body": "Confirmation as per Regulation 74(5) of SEBI (DP) Regulations for the quarter ended 31.03.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5af7b509-0a7d-47f3-85d4-2231cb4ddf20.pdf",
            "news_date": "2024-04-05 12:29:33"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Reg. 7(3) \u2013 Compliance Certificate (RTA & Compliance Officer)",
            "caption": "Regulation 7(3) Certificate For The Financial Year Ended 31.03.2024.",
            "news_body": "Compliance certificate as per Regulation 7(3) of SEBI(LODR) Regulations,2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=303b77d5-47a4-4c4e-a8dd-a4695e4f9149.pdf",
            "news_date": "2024-04-04 10:48:31"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "",
            "descriptor": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure",
            "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
            "news_body": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>BAL PHARMA LTD.</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85110KA1987PLC008368</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr)</td> <td>44.81</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>BBB-</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>ACUITE RATINGS & RESEARCH LIMITED</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table>  <br/><br/> <div> <div style=''float:left;''> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No</div> <br/><br/><br/> <div style=''float:left;''> Name of the Company Secretary: Abdul Basith <br/>  Designation: Company Secretary  <br/> EmailId: secretarial@balpharma.com</div> <div ''style=float:left;margin-left:50px;''> Name of the Chief Financial Officer: Bharath Bhushan <br/> Designation: CFO <br/> EmailId: secretarial@balpharma.com</div> </div> <div> <br/> Date: 02/04/2024<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e95cc8df-7839-46fe-90f8-0728d1b38f53.pdf",
            "news_date": "2024-04-02 14:55:15"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Insider Trading / SAST",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Pursuant to the Code of Conduct of the Company and as per the amended provisions of SEBI(Prohibition of Insider Trading) Regulations,2015, We wish  to inform the exchanges that the trading window for dealing with the securities of the Company on the designated persons and their immediate relatives will be closed from 1st April 2024 and up to 48 hours of the declaration of the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2024.The date of the Board meeting for declaration of audited financial results will be intimated to the  exchanges in due course.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc81bb06-574a-481a-8cf0-86d9aa4085ba.pdf",
            "news_date": "2024-03-22 15:42:12"
        },
        {
            "co_code": 4704,
            "bse_code": 524824,
            "isin": "INE083D01012",
            "ann_type": "Company Update",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "We are submitting to the  exchanges copies of the newspaper advertisements of abridged standalone and consolidated financial results of the Company for the quarter and nine months ended 31.12.2023, announced by the Company on 12.02.2024 and published in Financial Express ( English) and Sanjayvani ( Kannada ) on 13.02.2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3c6348cc-0add-4a34-a883-3d59270facbc.pdf",
            "news_date": "2024-02-14 12:30:34"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 31.12.2023.",
            "news_body": "Unaudited standalone and consolidated Financial results for the quarter and 9 months ended 31.12.2023.",
            "news_id": "06744409-c866-4e7b-a323-bb67874da93c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=77b3a08c-6431-41c2-99f7-6f81a4ac327c.pdf",
            "news_date": "2024-02-12 18:00:01",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2023.",
            "news_body": "The Board of Directors of the Company has inter alia taken on record and approved the unaudited financial result of the Company for the quarter and half year ended 30.09.2023",
            "news_id": "11666253-a9a8-447a-b409-c521664d7804",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=00eaa93b-8e87-4ee1-adb0-56055f4fcfe6.pdf",
            "news_date": "2023-11-08 17:58:00",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results - Stand Alone And Consolidated For The Quarter And Year Ended 31.03.2023",
            "news_body": "The Board of Directors of the Company has met today and inter alia transacted the following business.<BR> <BR> 1.Approved the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended 31.03.2023. A copy of the Audited financial statements (Standalone and Consolidated) along with auditors reports with unmodified opinion are enclosed with this letter for submission to the exchanges. <BR> <BR> 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each i.e 10%, subject to the approval of members at the ensuing Annual General Meeting of the Company. <BR> <BR> 3.Appointed Mr.M.R Krishna Murthy (Membership No. 7568) as Cost Auditor , Mr.Parameshwar Bhat (Membership No.8860) as Secretarial Auditors and Messrs. Murugesh & Co ( Membership No.002233S) as internal auditors of the Company for the financial year 2023-2024.<BR> <BR> The meeting commenced at 4.45 P.M and concluded at 6.20 P.M on 29.05.2023.<BR>",
            "news_id": "4df15b80-d780-4c75-a4c9-1e40d91b90db",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27ca1282-0c8b-4958-b8a4-f1bc67065e2a.pdf",
            "news_date": "2023-05-29 19:28:24",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2022.",
            "news_body": "Board of Directors of the Company has met today and inter alia transacted the following business.<BR> <BR> 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and nine months ended 31.12.2022. A copy of the standalone and consolidated financial results together with the limited review reports issued by the statutory auditors of the Company with un modified opinion, is enclosed.<BR> <BR> The Board meeting commenced at 4.30 p.m and concluded at 6.20 p.m on 06.02.2023.<BR> <BR> <BR> <BR>",
            "news_id": "2c64f97c-fb27-48e9-87d5-01a8aafdf8e3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=79efc482-da67-45a6-84d6-c62654bd7c52.pdf",
            "news_date": "2023-02-06 18:42:57",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions",
            "news_body": "We are submitting to the exchanges statement of the related party transactions of the Com[pany for the half year ended 30.09.2022.",
            "news_id": "74a3b7bb-4af6-4168-a397-0bb4fa4df1fb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3cfda30a-5b0b-4f03-85b0-b58f27e42d8a.pdf",
            "news_date": "2022-11-28 13:47:54",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2022.",
            "news_body": "Board of Directors of the Company has met today and inter alia transacted the following  business.<BR> <BR> 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and half year ended 30.09.2022. A copy of the standalone and consolidated financial results together with the balance sheets, cash flow statements and limited review reports issued by the statutory auditors of the Company with un modified opinion is enclosed .<BR> <BR> 2.Convened Extra Ordinary meeting of the shareholders of the Company on 14th December 2022 to take their approval for filing application with NCLT for the merger of Golden Drugs Pvt Ltd, a wholly owned subsidiary of the Company.<BR> <BR> 3.Approved the allotment of 1,17,500 equity shares to the employees of the Company who has exercised the stock options vested on them, under Bal Pharma Ltd employee stock option plan 2014. <BR> <BR> The Board meeting commenced at 5.30 p.m and concluded at 6.20 p.m on 14.11.2022.<BR>",
            "news_id": "f334876b-b3a3-4f72-8352-93b57d9395ba",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3307a810-c82b-464f-9b69-8ecc771b3ea8.pdf",
            "news_date": "2022-11-14 19:07:25",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Audio Visual recording of the webinar can we assessed through the following weblink https://www.balpharma.com/ip",
            "news_id": "cc86aceb-e484-4fe4-963c-8e9812ee4027",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8c57bc7f-1788-4b09-bfe5-c2095e5c7f63.pdf",
            "news_date": "2022-09-23 12:24:37",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "We are submitting the revised Investor presentation on the performance of the Company for the quarter ended 30.06.2022.",
            "news_id": "76a8f838-f5f7-4a1f-a0c2-fea11b110d2d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4561806c-b55c-4560-aaec-2d919e9d735e.pdf",
            "news_date": "2022-09-07 16:51:35",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for Q1 FY 23",
            "news_id": "04fe1663-f557-4eff-8c22-f7f399ca22ee",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a9ffac35-8f79-45a2-b88b-9a88e106e075.pdf",
            "news_date": "2022-09-06 17:07:27",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Financial Results For The Quarter Ended 30.06.2022.",
            "news_body": "Board of Directors of the Company at their meeting held on 11.08.2022 has inter alia taken on record and  approved the Un-audited financial results of the Company for the quarter ended 30.06.2022. <BR> <BR> Financial results along with the limited review reports issued by the statutory auditors of the Company are enclosed.",
            "news_id": "0f58910f-4b75-4fb3-b25a-2f530ef466a6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d03990f7-f009-4d3f-a463-f7079c56284d.pdf",
            "news_date": "2022-08-11 16:12:41",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "Board of Directors of the Company has inter alia taken on record and approved the un-audited financial results ( stand alone & consolidated ) of the Company for the quarter ended 30.06.2022.",
            "news_id": "bac22536-4e8f-4314-896e-acf3beac0ba3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cb293dc8-2aa9-43bb-8842-5998a1be3e99.pdf",
            "news_date": "2022-08-11 16:06:59",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Declaration Of Unmodified Opinion_ Audited Financial Results",
            "news_body": "Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare and confirm that the Statutory Auditors of the Company viz. NSVM & Associates, Chartered Accountants, having membership # 010072S have issued audit report with Unmodified opinion on audited Standalone and Consolidated Financial Statements of the Company, for the quarter and year ended March 31, 2022.<BR> <BR> The declaration of unmodified opinion was confirmed by the auditors in their audit report and the same was submitted to the exchanges vide our submission dated 30.05.2022.<BR> <BR>",
            "news_id": "77ebf227-bb92-402c-a651-0ea438f79dc7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fe9849f2-0d7b-4325-bad7-94e45e25c951.pdf",
            "news_date": "2022-06-08 15:27:00",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For F.Y 2021-22.",
            "news_body": "The Board of Directors of the Company has met today and inter alia transacted the following business.<BR> <BR> 1.Approved the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2022. A copy of the Audited financials (Standalone and Consolidated) along with auditors report's are enclosed with this letter for submission to the exchanges. <BR> <BR> 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each, payable subject to the approval of members at the ensuing Annual General Meeting of the Company. <BR> <BR>",
            "news_id": "6b5de63a-08e4-4f0a-8672-f6d6ccc1141a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b2767d4-b010-466c-bf23-3cfde80350a9.pdf",
            "news_date": "2022-05-30 18:20:44",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "The Board of Directors of the Company has met to day and inter alia transacted the following business.<BR> <BR> Taken on record and approved the Unaudited financial results of the Company for the quarter ended 31.12.2021. Copy of the standalone and consolidated financial results along with the limited review reports with unmodified opinions issued by the statutory auditors of the Company is enclosed, for submission to the exchanges.<BR> <BR> The meeting commenced at 16.30 and concluded at 18.00 hours on 10.02.2022.<BR>",
            "news_id": "51c2d275-8ac4-4981-b8ff-215eb67b1eeb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9115eaf7-7692-4132-99a3-4298b6609a48.pdf",
            "news_date": "2022-02-10 18:38:48",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Standalone & Consolidated Financial Results_31.12.2021",
            "news_body": "The Board of Directors of the Company has met to day and inter alia transacted the following business.<BR> <BR> Taken on record and approved the Unaudited financial results of the Company for the quarter ended 31.12.2021. Copy of the standalone and consolidated financial results along with the limited review reports with unmodified opinions issued by the statutory auditors of the Company is enclosed, for submission to the exchanges.<BR> <BR> The meeting commenced at 16.30 and concluded at 18.00 hours on 10.02.2022.<BR>",
            "news_id": "3969ffc8-d8ed-4d4b-affb-1d2a5bcf124b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f2f096bc-a9d8-4c97-bafb-933488b73e26.pdf",
            "news_date": "2022-02-10 18:15:57",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For Quarter And Half Year Ended 30.09.2021",
            "news_body": "We are resubmitting the higher resolution , clear and legible financial results of the Company for the quarter and half year ended 30.09.2021.",
            "news_id": "0eb4fc22-b885-40fd-b41c-edec55ca130a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d00fbc4b-bf39-496f-9083-095d30f5da82.pdf",
            "news_date": "2021-12-09 15:32:12",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Standalone & Consolidated Financial Results_30.09.2021",
            "news_body": "The Board of Directors of the Company has met to day and inter alia transacted the following business.<BR> <BR> 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and half year ended 30.09.2021. Copy of the standalone and consolidated financial results along with the limited review reports issued by the statutory auditors of the Company is enclosed, for submission to the exchanges.<BR> <BR> The meeting commenced at 16.30 p.m and concluded at 18.00 on 11.11.2021.<BR> <BR>",
            "news_id": "e32dd6a0-b7c2-4598-ad93-49e246908fb2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4c71194f-4bee-471b-ae05-9b04a893554e.pdf",
            "news_date": "2021-11-11 18:06:20",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The  Board Meeting",
            "news_body": "The Board of Directors of the Company has met to day and inter alia transacted the following business.<BR> <BR> 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and half year ended 30.09.2021. Copy of the standalone and consolidated financial results along with the limited review reports issued by the statutory auditors of the Company is enclosed, for submission to the exchanges.<BR> <BR> The meeting commenced at 16.30 p.m and concluded at 18.00 on 11.11.2021.<BR> <BR> <BR>",
            "news_id": "23e6209e-bf4d-430a-ae5d-3cc59c2e8256",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cd05f26a-0059-4eb3-8102-fd260cdc6b24.pdf",
            "news_date": "2021-11-11 17:58:32",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30.06.2021.",
            "news_body": "Out come of the Board Meeting.<BR> <BR> The Board of Directors of the Company has met to day and inter alia transacted the following business.<BR> <BR> 1.Taken on record and approved the Unaudited financial results of the Company for the quarter ended 30.06.2021. Copy of the stand alone and consolidated financial results along with the limited review reports issued by the statutory auditors of the Company is enclosed, for submission to the exchanges.<BR> <BR> 2.Approved the grant of 4,16,500 stock options to the employees of the Company under Bal Pharma Ltd - Employee Stock Option Plan -2014.<BR> <BR> The meeting commenced at 16.30 p.m and concluded at 17.30 on 10.08.2021.<BR>",
            "news_id": "6c5e3543-c9b6-4024-a00f-be211586b7b6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=415cf4a0-4965-4cd4-bf52-35cb3327a26e.pdf",
            "news_date": "2021-08-10 17:43:14",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Declaration Of Unmodified Opinion.",
            "news_body": "Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare and confirm that the Statutory Auditors of the Company viz. NSVM & Associates, Chartered Accountants, having membership # 010072S have issued audit report with Unmodified opinion on audited Standalone and Consolidated Financial Statements of the Company, for the year ended March 31, 2021.<BR> <BR>",
            "news_id": "99fbb52e-8196-4359-bb86-a5f5ba7990cc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d458540c-29af-4f39-a140-532d219f28e1.pdf",
            "news_date": "2021-07-06 12:21:32",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For Quarter And Financial Year Ended 31.03.2021.",
            "news_body": "The Board of Directors of the Company has met today and inter alia transacted the following business.<BR> 1.Approved the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2021. A copy of the Audited financials (Standalone and Consolidated) along with audit report's are enclosed with this letter for submission to the exchanges. <BR> 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each, payable subject to the approval of members at the ensuing Annual General Meeting of the Company. <BR> 4. Decided to convene the 34th Annual General Meeting of the Company on Friday 24th September, 2021, by audio visual means.<BR> 5.Decided to close the Register of Members and Share Transfer books of the Company from 18th September 2021 to 24th September 2021 (Both days inclusive).<BR> 6.The Board considered and authorised Mr.Shailesh Siroya, Managing Director  to undertake restructuring process of the group Companies, subject to various legal and taxation aspects.   <BR> <BR>",
            "news_id": "50b4c7d8-ee3d-436f-b471-0a9411a105c4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d7df3c76-832b-4931-a19f-bbef0a961316.pdf",
            "news_date": "2021-06-29 17:53:42",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        }
    ]
}